Chinese Japanese Germany Korea


Indications and Usage Mechanisms of Action clinical trials
Finasteride structure
Chemical Name:
Molecular Formula:
Formula Weight:
MOL File:

Finasteride Properties

Melting point:
253 °C
Boiling point:
576.6±50.0 °C(Predicted)
405 -59° (c = 1 in methanol)
1.065±0.06 g/cm3(Predicted)
storage temp. 
room temp
DMSO: 32 mg/mL, soluble
white to beige
Water Solubility 
CAS DataBase Reference
98319-26-7(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
ATC code
EPA Substance Registry System
1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (98319-26-7)
  • Risk and Safety Statements
Signal word  Warning
Hazard statements  H302
Precautionary statements  P301+P312+P330-P264-P270-P301+P312a-P330-P501a
Hazard Codes  Xn,T,Xi
Risk Statements  22-61-60-36/37/38
Safety Statements  36/37/39-45-53-36-26-24/25
WGK Germany  3
RTECS  CL5245000
HS Code  29379000

Finasteride price More Price(16)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 34202 Finasteride VETRANAL 98319-26-7 100mg $160 2020-08-18 Buy
Sigma-Aldrich Y0000090 Finasteride European Pharmacopoeia (EP) Reference Standard 98319-26-7 $190 2021-03-22 Buy
Sigma-Aldrich Y0001604 Finasteride for peak identification European Pharmacopoeia (EP) Reference Standard 98319-26-7 $190 2021-03-22 Buy
Sigma-Aldrich 1270402 Finasteride United States Pharmacopeia (USP) Reference Standard 98319-26-7 200mg $366 2021-03-22 Buy
TCI Chemical F0675 Finasteride >98.0%(GC) 98319-26-7 200mg $52 2021-03-22 Buy

Finasteride Chemical Properties,Uses,Production

Indications and Usage

Finasteride is a basic drug to treat benign prostatic hyperplasia and prostatitis, a synthetic 4-nitrogen steroid hormone compound and a sex hormone drug.
It is used for benign prostatic hyperplasia, men's prostatic fat and other diseases. Finasteride is the only oral drug approved by the US Food and Drug Administration (FDA) to treat male pattern baldness.

Mechanisms of Action

Finasteride can selectively inhibit 5α-reductase, changing the conversion process of testosterone into 5α dihydrotestosterone (DHT), decreasing androgen levels in prostate cells, and prostate-specific antigens in serum, decreasing prostate swelling, and increasing urine flow rate, thereby alleviating the symptoms of prostatic hyperplasia. It acts by selectively blocking androgen stimulation of the prostate, but affects sexual function very rarely. Meanwhile, due to blocking of testosterone conversion and reduced synthesis of dihydrotestosterone, it can reduce dihydrotestosterone levels in the serum and scalp hair follicles, recovering the function of previously inhibited hair follicles, promoting hair growth and preventing loss.

clinical trials

Three controlled clinical trials were performed in men (18 to 41 years), with mild-to-moderate degrees of androgenetic alopecia. In these studies, 1879 men ingested either a 1- mg finasteride tablet or placebo tablet once daily for 12 months; after 12 months, finasteride-treated patients were switched to placebo and placebo-treated patients were switched to finasteride and they were followed for an additional 12 months. Clinical improvement was seen as early as 3 months in finasteride-treated patients and hair regrowth continued throughout the trial. Finasteride also had a stabilizing effect on hair loss, which was maintained through the second year of treatment. Hair counts in placebo-treated patients decreased during the study. Finasteride was generally well tolerated in these studies. Some men, however, experienced decreased libido, difficulty in achieving an erection, and decreased semen volume (<2% of patients in each case). These side effects resolved in 58% of the men who continued treatment and completely abated upon discontinuation of the drug.


Finasteride, a novel 4-azasteroid, is a breakthrough in the treatment and control of benign prostatic hyperplasia. Mechanistically, it inhibits the prostatic-specific enzyme 5-alpha reductase, thereby decreasing the conversion of testosterone to dihydrotestosterone. It is reportedly effective in reducing urinary symptoms and prostatic volume and increasing maximal urinary flow rate. Finasteride is also being investigated as a treatment for prostatic cancer.

Chemical Properties

Off-White Crystalline Powder


Merck (U.S.A.)


Inhibitor of 5α-reductase, the enzyme which converts testosterone to the more potent androgen, 5α-dihydrotestosterone. Antialopecia agent.


Treatment of benign prostatic hyperplasia and androgenetic alopecia


Finasteride is a specific inhibitor of steroid type II 5α-reductase, an intracellular enzyme that converts testosterone to DHT. By inhibiting type II 5α-reductase, this conversion is blocked, resulting in significant decreases in serum and tissue DHT concentrations. Merck & Co. developed finasteride as an oral treatment for androgenetic alopecia after men taking finasteride (5 mg/ day) for prostate enlargement noticed regrowth of their hair.
Finasteride is indicated for use in men only. Women of childbearing age cannot take finasteride because it may cause hypospadia (a developmental abnormality of the penis) in the male offspring if taken during pregnancy.


ChEBI: An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.


Finasteride (Proscar) is a 5-reductase inhibitor that blocks the conversion of testosterone to DHT in target tissues. Since DHT is the major intracellular androgen in the prostate, finasteride is effective in suppressing DHT stimulation of prostatic growth and secretory function without markedly affecting libido. It is approved for the treatment of benign prostatic hyperplasia. Although there is usually some regression in the size of the prostate gland following administration of finasteride, clinical response may take 6 to 12 months. If the obstructive symptoms are severe, there is often not enough time to allow this compound to work.The principal adverse effects of finasteride are impotence, decreased libido, and decreased volume of ejaculate. The compound is generally well tolerated in men.

Manufacturing Process

In a flask equipped with an overhead stirrer, a nitrogen inlet, and reflux condenser was placed 840 ml of dry THF and 20.0 g of 17β-carboxylate 17β- carbomethoxy ester of 4-aza-5α-androst-1-en-3-one (synthesized according to Patent US 4,377,584, issued Mar. 22,1883, and J. Med. Chem., 29, 2298 (1986)). The resulting slurry was cooled to -5-10°C, and 27.6 mL of tbutylamine was added. A solution of ethylmagnesium bromide in THF (122 mL, 2 M) was added maintaining the temperature of the reaction mixture below 10°C. The reaction mixture was heated at reflux for 12 hours and was added to a cold (10°C) solution of 25% ammonium chloride in water. The mixture was warmed to 25°C and allowed to settle. The THF solution was separated and concentrated by atmospheric distillation to 200 mL and the product was crystallized by adding approximately 600 mL of dilute aqueous HCl. The resulting white solid was isolated by filtration and was dried at 70°C under vacuum to give 21.7 g (97% yield) 2-butyl-1-(4-carboxybenzyl)-4- chloroimidazole-5-acetic acid of finasteride. The finasteride can be purified by conventional procedures, e.g. recrystallization from methylene chloride/ethyl acetate or acetic acid/water, melting point 261°C.

brand name


Therapeutic Function


Biological Activity

Antiandrogen that inhibits type II 5 α reductase (IC 50 = 65 nM). Suppresses the conversion of testosterone to dihydrotestosterone. Reduces prostatic dihydrotestosterone levels and prostate size in vivo . Orally active.


The mean oral bioavailability of finasteride is 65%, as shown in Table 45.4, and is not affected by food. Approximately 90% of circulating finasteride is bound to plasma proteins. Finasteride has been found to cross the blood-brain barrier, but levels in semen were undetectable (<0.2 ng/mL). Finasteride is extensively metabolized in the liver, primarily via CYP3A4 to two major metabolites: monohydroxylation of the t-butyl side chain, which is further metabolized via an aldehyde intermediate to the second metabolite, a monocarboxylic acid. The metabolites show approximately 20% the inhibition of finasteride for 5α-reductase. The mean terminal half-life is approximately 5 to 6 hours in men between 18 and 60 years of age and 8 hours in men older than 70 years of age. Following an oral dose of finasteride, approximately 40% of the dose was excreted in the urine as metabolites and approximately 57% in the feces. Even though the elimination rate of finasteride is decreased in the elderly, no dosage adjustment is necessary. No dosage adjustment is necessary in patients with renal insufficiency. A decrease in the urinary excretion of metabolites was observed in patients with renal impairment, but this was compensated for by an increase in fecal excretion of metabolites. Caution should be used during administration to patients with liver function abnormalities, because finasteride is metabolized extensively in the liver.

Clinical Use

The selective inhibition of the type 2 5α-reductase isozyme produces a rapid reduction in plasma DHT concentration, reaching 65% suppression within 24 hours of administering a 1-mg oral tablet (106). At steady state, finasteride suppresses DHT levels by approximately 70% in plasma and by as much as 85 to 90% in the prostate. The remaining DHT in the prostate likely is the result of type 1 5α-reductase. The mean circulating levels of testosterone and estradiol remained within their physiological concentration range. Long-term therapy with finasteride can reduce clinical significant end points of BPH, such as acute urinary retention or surgery. Finasteride is most effective in men with large prostates. Finasteride has no affinity for the AR and no androgenic, antiandrogenic, estrogenic, antiestrogenic, or progestational effects.

Veterinary Drugs and Treatments

Finasteride may be useful in treating the benign prostatic hypertrophy in canine patients. Because of the drug’s relative expense and the long duration of therapy required to see a response, its usefulness may be limited in veterinary medicine.
It may also be useful in the adjunctive treatment of adrenal disease in ferrets.

Finasteride Preparation Products And Raw materials

Raw materials

Preparation Products

Finasteride Suppliers

Global( 514)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Baoji Guokang Bio-Technology Co., Ltd.
09173909592 CHINA 9440 58
Shanghai Payne Pharmaceutical Technology Co.Ltd
18678586262 021-58123769 China 1355 58
Beijing Yibai Biotechnology Co., Ltd
0086-182-6772-3597 CHINA 420 58
15377521700 +8615377521700
027-81302088 CHINA 869 58
ShenZhen Ipure Biology import and export company co.,ltd
18071025641 18071025641 CHINA 11336 58
Baoji Guokang Healthchem co.,ltd
09178656283 CHINA 9474 58
Shanghai Biolang Biotechnology Co., Ltd.
+8613669031409 China 296 58
Hebei Lingding Biological Technology Co., Ltd
19933155420 CHINA 942 58
Hong Kong Excellence Biotechnology Co., Ltd.
wickrme:chemical888 China 764 58
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497 CHINA 1817 55

View Lastest Price from Finasteride manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2021-12-09 Finasteride
2021-12-07 Finasteride
US $30.00 / g 1000g 99% 20ton/month Wuhan Aoliqisi New Material Technology Co., Ltd.
2021-12-07 Finasteride
US $200.00 / KG 1KG 99% 9000kg/per week Hebei Lingding Biological Technology Co., Ltd

98319-26-7(Finasteride)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved